A Rival to the Renal Denervation Therapy Procedure?

Vascular Dynamics is taking a different approach in its bid to treat patients with drug-resistant hypertension. While firms like Medtronic have gravitated toward using renal denervation to treat drug- resistant hypertension, Vascular Dynamics is developing a stent-like application to treat the condition, which effects more than 100 million patients in the U.S. The Mountain View, CA-based company said it has enrolled the first patients in a pivotal trial. The company’s CALM-2 study is designed to establish safety and efficacy of the endovascular baroreceptor amplification (EVBA) procedure using the MobiusHD device as a treatment for drug-resistant hypertension. “This is an endovascular neuro-receptor reflex activation device that is a permanent carotid stent-like implant,” Gregg Stone, MD, Co-Principal Investigator of the CALM-2 trial and Director of Cardiovascular Research and Education for NewYork-Presbyterian/Columbia University Medical Center and Co-Director of Medical Research and Education at the Cardiovascular Research Foundation,toldMD+DI. The CALM-2 trial is targeting enrollment of up to 300 patients at leading institutions across the U.S. and Europe. “[The technology] has been used in a modest number of patients and open-label studies,” Stone said. “It has been shown in patients with resistant hypertension to be quite remarkably effective. Now the question is...
Source: MDDI - Category: Medical Devices Authors: Tags: Business Cardiovascular Source Type: news